![Virginie Miath](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Virginie Miath holds current positions as Non-Executive Director at BioSenic SA starting in 2026, Investment Director at Capital Grand Est SAS, Independent Director at Aton SA since 2023, and Member of the Supervisory Board at Firalis SA.
Actieve functies van Virginie Miath
| Bedrijven | Functie | Begin |
|---|---|---|
| ATON | Directeur/Bestuurslid | 20-12-2023 |
| BIOSENIC SA | Directeur/Bestuurslid | 29-01-2026 |
Firalis SA
 Firalis SA BiotechnologyHealth Technology Engages in the discovery and development of biomarker-based diagnostics | Directeur/Bestuurslid | - |
Capital Grand Est SAS
 Capital Grand Est SAS Investment ManagersFinance Capital Grand Est is an active manager which invests in France, Germany and Switzerland. For early-stages financing, the firm typically invests between EUR 250,000 to EUR 3.6 million and for later-stages and growth between EUR 1 million to EUR 5 million. Capital Grand Est invests as a minority or majority stakeholder. | Private Equity Investor | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
34
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Hybrigenics SA
 Hybrigenics SA Pharmaceuticals: MajorHealth Technology Develops therapeutic molecules and genomics | Health Technology |
Firalis SA
Firalis SA BiotechnologyHealth Technology Engages in the discovery and development of biomarker-based diagnostics | Health Technology |
Capital Grand Est SAS
Capital Grand Est SAS Investment ManagersFinance Capital Grand Est is an active manager which invests in France, Germany and Switzerland. For early-stages financing, the firm typically invests between EUR 250,000 to EUR 3.6 million and for later-stages and growth between EUR 1 million to EUR 5 million. Capital Grand Est invests as a minority or majority stakeholder. | Finance |
BioSenic SA
 BioSenic SA BiotechnologyHealth Technology Engages in medical research and develops drugs | Health Technology |
